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Abstract: Despite many hypotheses that have been challenged, the etiology of endemic 
nephropathy (EN) is still unknown. At present, the implications of aristolochic acid (AA) 
and mycotoxins (ochratoxin A—OTA and citrinin—CIT) are under debate. AA-theory is 
based on renal pathohistological similarities between Chinese herbs nephropathy (CHN) 
and EN, findings of AA-DNA adducts in EN and in patients with urinary tract tumors 
(UTT),  as well as the  domination of A:T→T:A transversions in the p53 mutational 
spectrum of UTT patients,  which  corresponds with  findings of such mutations in   
AA-treated rats. However, exposure pathways of EN residents to AA are unclear. 
Experimental studies attempting to deduce whether nephrotoxins OTA and CIT appear at 
higher frequencies or levels  (or both)  in  the  food and blood or urine of EN residents 
support the mycotoxin theory. Also, some molecular studies revealed the presence of 
OTA-DNA adducts in the  renal tissue of EN and UTT patients. In this review,  data 
supporting or arguing against AA and mycotoxin theory are presented and discussed. 
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1. Introduction 
Endemic nephropathy (EN) is a chronic kidney disease that affects the human population of some 
rural areas in Bosnia and Herzegovina, Bulgaria, Croatia, Romania, and Serbia. In Croatia, the EN area 
is restricted to 14 villages in the western part of Brodsko-Posavska County. The EN was first described 
in the late 1950s,  and an association between the disease and urinary tract tumors (UTT) was 
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recognized in the 1970s. This fatal disease is characterized by a focused and restricted geographical 
distribution, occurrence in farming households, high mortality from uremia, and high incidence of 
UTT. The endemic nature of the disease implicates the involvement of environmental factors, 
particularly of naturally occurring toxins and carcinogens. In the past 50 years, many studies exploring 
the possible role of various environmental factors in EN and UTT have been performed, and this 
includes research on heavy metals and minerals, bacteria (β-haemolytic streptococci, E. coli,  and 
Leptospira spp.) and viruses (coronaviruses), Pliocene lignites, aristolochic acid (AA), and mycotoxins 
(particularly ochratoxin A, OTA) [1–5].  
Aristolochic acid is a generic name for family of nitrophenantrene derivatives that can be found in 
the stem and seeds of Aristolochia species, which occur in flooded areas in many parts of the world, 
including EN areas. Between 1990 and 1992,  a number of cases of interstitial nephropathy were 
reported in young women in Belgium who were undergoing a slimming regimen with Chinese herbs. 
Chemical analysis of these Chinese herbs remedies did not reveal nephrotoxic contaminants of fungal 
or plant origin,  such as ochratoxin A or AA [6]. Vanhaelen et al. [7] used a different analytical 
procedure for AA detection, but again, AA was never found in these weight-loss pills. In another 
study, the same group of investigators detected AA, instead of tetrandrine, in 10 out of 12 herbal 
powders in Belgium pharmacies sold between 1990 and 1992 under the name S. tetrandra. However, 
these findings are not related to the reported renal failure in women involved within the weight-loss 
program. It seems that other chemicals, rather than AA alone, might be involved in producing the 
nephrotoxic and carcinogenic effects related to the weight-loss pills [8]. Nortier et al. [9] found high 
level of AA-related DNA adducts in renal specimens obtained from the Chinese herbs nephropathy 
(CHN) patients (38/39) involved in weight-loss program, which supported chronic exposure to this 
phytotoxin. The authors also detected lower levels of OTA-related DNA adducts in four  out of   
25 samples, and concluded that OTA does not have a key role in the nephropathy of these CHN 
patients. Cosyns et al. [10] tested the nephrotoxic effects of pure AA and slimming regimen + AA on 
rats. At a dose of 10 mg/kg per os 3 months, no renal fibrosis was detected, but tumors of the renal 
pelvis, urinary bladder, and forestomach were found in rats. In addition, 2/4 rats treated with the 
slimming regimen + AA developed tubulointestitial fibrosis, which suggested that the toxicity of AA 
could be potentiated. Some clinical and morphological features of CHN (anemia, proteinuria, renal 
athrophy, interstitial fibrosis, and urothelial malignancy) are similar to those observed in EN patients 
[11,12]. About 35 years ago, Ivić [13] observed that the seeds of birthwort A. clematitis (vučja stopa in 
Croatian) were sometimes co-mingled with wheat grain, and suggested that exposure of EN patients to 
AA could occur through contamination of flour and baked bread.  
In the 1970s, similarities between EN and ochratoxin A (OTA)-induced nephropathy in pigs were 
observed, and it was suggested that this mycotoxin could be involved in the etiology of EN. Since 
then, the nephrotoxic and carcinogenic properties of OTA have been demonstrated on a number of 
experimental animals including pigs, rats, mice, or poultry [1–4,14]. In the past few decades, many 
surveys in EN areas have confirmed the presence of OTA in a variety of diet products, including 
cereals and smoked meat [15,16]. It was also found that people in EN regions are often exposed to 
higher concentrations of OTA, which was confirmed by the presence of higher levels of this toxin in 
the blood and urine of subjects from EN regions,  as compared to those living in EN-unaffected  
areas [17–19].  Toxins 2010, 2 
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According to current research data of Grollman et al. [20], AA is a “prime suspect” in the etiology 
of EN, but the role of mycotoxins in the development of this disease could not be excluded. This 
review is aimed at discussing the hypotheses on the implication of AA and mycotoxins in the etiology 
of EN. 
2. Epidemiological and Clinical Features of EN and CHN 
In the period of  1991–2002,  the average general mortality in  the  EN region of  Croatia was 
10.3/1000, while the specific mortality for EN patients was 0.58/1000 (men) and 0.72/1000 (women). 
The average age of death of EN patients was 67.7 (men) and 70.3 (women), which is significantly 
higher than in the sixties (45.1 years). Between 1995 and 2002, the specific mortality from UTT in 
Croatian EN region (6.902/100000) was 55-times higher than in the  entirety of  Croatia 
(0.126/100000). Similar findings were reported for EN region of Bulgaria [3,21]. 
The epidemiological and clinical picture of EN and CHN has been recently reviewed [22]. The 
clinical features and pathomorphological changes of EN encompass tubular degeneration, interstitial 
fibrosis, hyalinization of glomeruli, enzymuria, loss of weight, pale skin, and absence of hypertension. 
Characteristic biochemical changes include mild proteinuria, glucosuria, mononuclear cell infiltration, 
increased blood urea nitrogen concentration, creatinine and urinary enzymes (γ-glutamyltransferase, 
alkaline phosphatase, lactate dehydrogenase), increased urinary pH, anemia, and increased IgM and 
IgG levels.  
Several clinical signs could be observed in both EN and CHN patients, such as tubular functional 
abnormalities, intersititial fibrosis, frequent malignancies of the urothelial tract (40%), normal arterial 
blood pressure, increased serum creatinine levels, mild tubular proteinuria, normoglycemic glucosuria, 
and anemia. The renal biopsies of EN and CHN patients revealed similar findings,  such as 
hypocellular interstitial sclerosis and tubular atrophy with normal or sclerosed glomeruli, depending on 
the stage of the disease [11,12,22].  
Despite some similarities, there are also some striking differences between EN and CHN that are 
manifested in some epidemiological features and in the course of the disease. EN affects only rural 
populations (aged 45–60) in restricted areas of Bosnia and Herzegovina, Bulgaria, Croatia, Romania, 
and Serbia, while CHN was observed as an epidemic in both urban and rural populations (aged 35–45) 
in Belgium (exclusively women),  as well as in other European countries and the  USA.  Familiar 
clustering is very important for EN, but not for CHN. Migrants develop EN after one or more decades 
of residence in EN regions, with a sex ratio of 1:1. In contrast, CHN is usually developed rapidly (6 to 
24 months  of exposure),  and  until now,  was dominant in young women exposed to a  slimming 
regimen containing AA. In addition, UTT development is very slow; it peaks one decade after the peak 
of EN, while the malignant progression of CHN takes two to six years. The other differences include a 
lack of uterohydronephrosis in EN, except in the cases of UTT, and less prominent involvement of the 
columns of Bertin in autopsied EN than in CHN patients [11,12,21,22]. In addition, endemic 
nephropathy in Tunisia and karyomegalic interstitial nephropathy has been associated with OTA. Both 
diseases share clinical and pathological similarities with EN [23]. 
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3. Evidences for the Implication of AA and Mycotoxins in EN  
3.1. Field exposure studies 
So far, there is no evidence that people in EN areas are exposed to AA through food consumption, 
particularly of bread made from homegrown wheat. Recently, Hranjec et al. [13] attempted to find, by 
means of questionnaire, whether EN patients were more exposed to AA than the healthy residents of 
EN villages in Croatia. The majority of subjects, including 90% of EN patients, recalled that A. 
clematitis was frequently found in the fields 20–30 years ago. Since then, all studied groups confirmed 
a significant increase in the use of herbicides, as well as a reduction of A. clematitis in the fields. 
However, there is no evidence to confirm that AA contamination of homemade bread occurred, or that 
the geographical pattern of AA exposure is consistent with occurrence of EN. In July of 2007, we 
conducted a similar questionnaire (unpublished data) among residents (N = 40), aged 20–80 years, in 
four EN villages (Lužani, Živike, Pričac, Slavonski Kobaš). Our questionnaire was designed to explore 
the subjects’ dietary habits and to find out if potential exposure to AA could occur through wheat flour 
contamination (Table 1).  
Table 1.  Questionnaire conducted in July of 2007 among residents (N  =  40) of four 
villages (Lužani, Živike, Pričac, Slavonski Kobaš) in the EN region of Croatia. 
Questions  Yes  No 
EN patients  2.5% (man, age 58)  97.5% 
UTT patients  2.5% (women, age 50)  97.5% 
EN family history  22.5%  77.5% 
*Sighting of A. clematitis in fields  77.5% (particularly in meadows)  22.5% 
Consummation of A. clematitis as a part of remedies  -  100% 
Unknown origin of flour for homemade bread  100%  - 
Consummation of smoked meat products  60% on daily basis, 40% periodically  - 
* Residents were shown the photo of A. clematitis and a specimen in the herbarium. 
The most important information collected is that the wheat was harvested in the mid of July, when 
A. clematitis is still immature. These observations are supported by the findings of Long and Voice 
[24]. The authors also indicated a possibility of ingestion of A. clematitis  as  a  medicinal herb. 
According to the results of our questionnaire, EN residents never used this plant as a regimen. The 
second important fact is that both 20–30 years ago, and today, residents of EN and non-EN villages in 
Brodsko-Posavska County brought their wheat to mill and exchanged it for sacks of flour of unknown 
origin. Taking into account these observations, it seems that human exposure to AA through wheat 
flour contamination is unlikely. Besides that, people in these regions frequently consume homemade 
smoked meat that is often contaminated by molds, as it was previously reported by Pepeljnjak and 
Blažević  [25]. Some elderly residents believe that mold  cover on smoked meat provides a good 
protection from flies and should not be removed. Also, some residents (16%) recalled that 20–30 years 
ago, moldy corn was used for the preparation of homemade brandy. These observations only partially 
illustrate the specific dietary habits that suggest higher exposure of EN residents to mycotoxins.  Toxins 2010, 2 
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The occurrence of OTA alone and the co-occurrence of OTA with other nephrotoxic mycotoxins in 
food and biological samples from EN and non-EN regions are summarized in Tables 2 and 3. Higher 
contamination of both OTA and citrinin (CIT), or both OTA and fumonisin B1 (FB1), were found in 
EN, as compared to non-EN, villages in Bulgaria, Croatia, and Serbia. Exposure of EN residents to 
these mycotoxins was confirmed by the identification of both OTA and CIT in blood and urine, and by 
higher sphinganine/sphingosine ratios  in urine (biomarkers of exposure to fumonisins) [26–36]. 
Studies in the non-EN regions of Croatia, and in other European countries, show that people are also 
exposed to a variable amount of OTA [18]. The estimated daily intake of OTA in non-EN regions of 
Croatia  (0.4 ng/kg b.w.) is lower than the tolerable daily intake proposed by the  World  Health 
Organization (16 ng/kg b.w.) [19]. However, studies conducted in EN areas of Croatia and Bulgaria 
confirmed that the  EN population is more frequently exposed to OTA,  and possibly to  other 
nephrotoxic mycotoxins, because of microclimatic conditions (high humidity) and specific dietary 
habits. Recently, OTA and CIT, but not AA, were detected in the food and urine of the members of 
three EN families, which confirmed dietary exposure of the EN population to mycotoxins, but not 
exposure to AA [33]. Analysis of weekly collected urine showed that 0.1 to 0.43 µg/L of OTA was 
present in 56% of the samples, while 0.37 to 2 µg/L of CIT was found in 9% of urines. Both toxins 
were detected in 6% of the samples. In addition, OTA was detected in 42% of the blood samples of EN 
patients, and in the blood of three karyomegalic nephropathy patients in Tunisia in high concentrations 
ranging from 1 to 1136 ng/mL, and from 102.63 to 1023 ng/mL, respectively [23]. 
Table 2. Occurrence of some nephrotoxic mycotoxins in food from EN and non-EN regions. 
  EN  non-EN   
Samples  Country (year)  Mycotoxin  %  range (µg/kg)  %  Range (µg/kg)  Ref. 
Smoked meat  Croatia (1978–80)  OTA  12–29  10–920  not analyzed  [25] 
Cereals  Croatia (1979–81)  OTA  45  10–68900  15  230–4700  [16] 
Beans  Bulgaria (1989–90)  OTA 
CIT 
36.6–40 
36–40 
25–260 
30–800 
5–8 
10–12 
10–220 
20–200 
[26,27] 
Corn  Bulgaria (1989–90)  OTA 
CIT 
~44 
40–43 
25–900 
50–1100 
5–8 
10–12 
10–235 
50–380 
[26,27] 
Corn  Croatia (1996–97)  OTA 
FB1 
9–50 
~96 
0.29–613.7 
12–11661 
10–20 
90.7–98 
0.26–223.6 
12–11278 
[28] 
Cereals  Bulgaria (1999)  OTA 
CIT 
35 
9.4 
<0.5–140 
<5–420 
35 
5 
0.65–1.9 
<5–6.5 
[29] 
Cereals  Croatia (1999–00)  OTA  81.8–100  0.019–160  11.1–88.9  0.019–32.3  [30] 
Beans  Croatia (2001)  OTA  not analyzed  37.7  0.25–0.92  [31] 
Corn  Croatia (2002)  OTA 
FB1 
FB2 
not analyzed  33.3 
100 
13 
0.73–2.54 
196.8–1377.6 
68.4–3084 
[32] 
Cereals  Croatia (2007)  OTA 
FB1 + FB2 + FB3 
16.2 
27 
2.5–31.7 
200–20700 
not analyzed  [33] 
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Table 3. Occurrence of OTA in biological samples from EN and non-EN regions. 
  EN  non-EN   
Samples  Country (year)  %  range  %  range  Ref. 
Pigs blood  Croatia 1979/81  0–15.7   0–37 µg/mL  not detected   
 
[10] 
Pigs liver  Croatia 1979/81  0–10.5  0–21 µg/kg  not detected 
Pigs kidney  Croatia 1979/81  5.2  16–27 µg/kg  not detected 
Human blood  Croatia 1985–94  0.2–4.5  2–50 ng/mL  0.4–2.4  1–10 ng/mL  [12] 
Human blood  Croatia 1997/98  not analyzed  59  0.21–15.9 ng/mL  [13,15] 
Human blood  Bulgaria 2002/03  100  0.1–10.9 µg/L  not analyzed   
[31]  Human urine  Bulgaria 2002/03  88–97%  0.01–1.91 µg/L  not analyzed 
3.2. Experimental studies 
Studies on experimental animals using AA and mycotoxins showed both  similarities and 
differences with EN in humans.  
After 17 to 21 months of intraperitoneal administration of 0.1 mg AA/kg b.w. to New Zealand 
White rabbit females, all animals displayed features that are common to both CHN and EN: intestitial 
fibrosis, increase in serum creatinine, glucosuria, proteinuria,  and anemia, and three out of   
12 developed urothelial tumors. Additionally, fibrotic changes were also observed in the stomach, with 
tumors in the peritoneal cavity [36]. Mice and rats were found to be less susceptible to AA; mice 
developed forestomach cancer after administration of 5 mg/kg b.w.  for 56 weeks,  and  rats after   
1 or 10 mg/kg b.w. for three months [38]. Rats developed renal pelvis and urinary bladder carcinoma 
after oral treatment with a relatively high dose of 10 mg AA/kg per day for five days [10,11]. 
Nephropathy in pigs taking feed that contained 0.2, 1, and 4 mg OTA/kg showed similarities with 
EN in humans, including major lesions in proximal tubules, followed by an increase of glucose and 
protein urinary excretion, elevated serum urea and creatinine levels,  and  an  increase of urinary 
enzymes activities  [39]. Pfohl-Leszkowicz and Manderville [21]  reviewed OTA carcinogenicity 
studies that confirmed OTA carcinogenic potency in rodents. B6C3F1 mice and Fischer rats developed 
renal tubular adenomas and carcinomas after 1 and 2 years of repeated, low dosage of OTA (40 µg in 
the diet and 21, 70, 210 µg/kg b.w. administrated intraperitoneally, respectively). At high doses, all 
rats presented karyomegalies.  Male rodents were more susceptible to OTA carcinogenicity than 
females: 72% of male rats and 16% of female rats developed renal carcinomas, while none of mice 
females had renal carcinoma or adenoma. Also, OTA induced adenocarcinoma and transitional cell 
carcinoma of the bladder in male rats only [40]. These sex-related differences have been recently 
explained by OTA binding to α2u-globulin, which is a carrier specific only to male rats. OTA is 
delivered to the proximal tubule epithelia, and thus cell exposure to the mycotoxin is increased in 
males, but not in female rats. There are no analogous androgen globulins in humans [41]. Also, male 
pigs, as well as male rats, showed different expressions of biotransforming enzyme in the kidneys than 
what females showed [42,43]. It is also important to note that EN tumors occur in the transitional cell 
tissues of the urinary tract,  and are not renal cell carcinomas. However, extrapolation from the 
urological carcinogenesis in experimental animals to human urinary tract tumors is especially difficult.  
Besides OTA, CIT and FB1 could also play an important role in development of EN, as well as 
other chronic kidney diseases of unknown etiology. This hypothesis is supported by the fact that these Toxins 2010, 2 
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mycotoxins have synergistic, or at least additive interactions in vitro and in vivo: (1) the combination 
of OTA and CIT was found to have additive or synergistic effects on kidney impairment in chicks, 
mices, rats, guinea pigs, dogs, and swines, and synergistic cytotoxic effects on porcine and human 
kidney cell lines [44–46]; (2) the cytotoxic synergism of OTA and FB1 was reported for green monkey 
kidney Vero cells, rat brain glioma cells, and human intestinal Caco-2 cells [47]; (3) the combined 
treatment of porcine kidney PK15 cells with OTA and FB1 applied in low doses resulted in dominant 
pro-oxidative and genotoxic additive interactions and synergistic apoptotic effects [48–50]; and   
(4) the combined FB1 and OTA treatment of rats resulted in synergistic oxidative DNA damage of the 
kidney cells and an increased rate of OTA-DNA adduct at doses that correspond to daily human 
exposure in Europe [51,52]. 
3.3. Bioactivation of AA and OTA and molecular studies 
A few enzymes and coenzymes are implicated in AA bioactivation, including hepatic cytochrome 
P450 enzymes (CYP1A1, CYP1A2) and NAD(P)H: quinone reductase (NQO1),  as well as renal 
NQO1, cytochrome P450 reductase (CPR) ,cyclooxygenase (COX),  and sulphotransferase 
(SULT1A1). These enzymes are involved in biotransformation of AA to N-hydroxyaristolactam I, 
which can be oxidized by renal peroxidases to form persistent adducts with DNA. These adducts are 
known to be mutagenic and can  initiate  tumors  [53,54]. dA-aristolactam (AL) and dG-AL DNA 
adducts have been identified in the renal cortex of EN and UTT patients (from 0.6 to 1.6 adducts/10
8 
nucleotides) but not in patients with other chronic kidney diseases [20]. It was also found that EN 
patients homozygous for the NQO1*2 allele were at increased risk of developing UTT (OR 13.75), 
suggesting the importance of NQO1 in AA activation and development of nephropathy [55,56]. An 
analysis of p53 mutations in AA-treated rats showed that predominant mutation was an A:T→T:A 
transversion [20]. Such a mutation, which accounted for 78% of all base substitutions, was also found 
in EN-associated UTT patients from Croatia and Bosnia, which supports the implication of AA in EN 
[20,57]. In contrast, in a study of blood samples of 90 Bulgarian EN patients, these p53 mutations were 
found only in 10% of the samples [58]. Pfohl-Leszkowicz [34,52] pointed out several reasons why the 
implication of AA in both CHN and EN is doubtful: (i) findings of AA-DNA adducts in Belgian 
women suffering from CHN [58] after intake of slimming pills in which AA was not detected [34];  
(ii) detection of AA-DNA adducts at high levels (five adducts/10
7 nucleotides) several years after the 
slimming regimen was stopped [59]; (iii) analysis of DNA samples of women taking slimming pills 
revealed OTA-DNA adducts, but no AA-DNA adducts [34]; (iv) AA-DNA adducts detected with 
Polyacrylamide Gel Electrophoresis (PAGE) that were reported by Grollman et al. [20] in EN and 
UTT patients was found questionable due to the low purity of DNA after extraction, as well as an 
unclear standard of comparison for AA-DNA adduct bands with those within the sample. However, 
AA-DNA adducts found in EN and UTT patients were confirmed by liquid chromatography 
electrospray ionization/multistage mass spectrometry (LC-ESI/MS/MS) techniques [20]. Nevertheless, 
OTA-related DNA adducts have not been analyzed in these EN patients and the occurrence of AA or 
AA-metabolites in food or urine samples from the EN region has not been tested.  
OTA genotoxic action is still under debate. Based on the current literature, OTA genotoxicity may 
be assigned as direct (DNA adduct formation) and indirect (oxidative DNA damage) OTA Toxins 2010, 2 
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mechanisms of action [21]. The experiments with microsomes from transgenic mice showed that the 
formation of OTA-mediated DNA adducts (analyzed by 
32P-postlabeling method) are under the control 
of biotransformation enzymes, such as CYP450 1B1, 2C9, COX, and LOX [21].
 A study on male Dark 
Agouti rats showed that the genotoxicity of OTA is related to CYP2C11 expression (corresponding to 
human CYP2C9), which is able to metabolize debrisoquine [42]. The roles of genetic polymorphisms 
in genes of some detoxifying and conjugation enzymes have been studied in EN patients. It was found 
that the CYP3A5*1 allele, as a marker for CYP3A5 expression in the human kidney, is associated with 
increased risk for EN (OR 2.41) [60]. It is possible that carriers of the CYP3A5*1 can more efficiently 
convert OTA into genotoxic metabolites [52].  Lebrun  et  al.  [61]  found  an  association between 
polymorphisms in GST conjugation isoenzymes and DNA damage induced by OTA. A mechanism by 
which OTA acts as a  genotoxin has been proposed [21].  The hydroquinone metabolite OTHQ 
covalently binds to DNA by an autoxidation or OTA in vitro activation in pig kidney microsomes or in 
human kidney cells. Additionally, OTA facilitates C8 deoxyguanosine adduct (O-C8-dG-OTA and  
C-C8-dG-OTA) formation in pigs, rodents, and human kidney cells, one of which is also formed when 
COX and LOX enzymes are highly expressed. It was shown that in vitro induction of LOX and COX2 
favored the formation of C-C8-dGMP-OTA, whereas CYP2C9 and COX1 favored the formation of the 
OTHQ-related DNA adduct [34]. Recently, the C-C8dGMP-OTA adduct has been identified by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) in the kidneys of Dark Agouti and Fischer 
rats (20–70 adducts/10
9 nucleotides) treated with approximately 8.3 and 6.8 mg of OTA/kg b.w. for 
three days, respectively [62]. These adducts were also detected in EN patients from Bulgaria, Croatia, 
and Serbia, as well as in French patients with kidney carcinoma (1–115 per 10
9 nucleotides), but not in 
non-EN patients [34]. Despite the evidence for the genotoxicity of OTA, other researchers could not 
detect OTA-related DNA adducts via the method of using radiolabeled OTA in combination with 
liquid scintillation counting or accelerator mass spectrometry, or by 32P-postlabeling and LC-MS/MS 
techniques [63]. Instead of direct OTA genotoxicity, they favor an indirect mechanism that involves 
oxidative stress, which is supported by OTA-mediated lipid peroxidation, formation of ROS, depletion 
of glutathione, and oxidative damage of DNA in vitro and in vivo [64]. These controversies have been 
explained by differences in the DNA extraction and 
32P-postlabeling methodology [21,52]. In addition, 
citrinin (CIT) generates DNA adducts in human kidney cells, which was also detected in the kidneys 
of EN patients. Nevertheless, AA-DNA adducts were not observed in these subjects [34]. Also, FB1 
enhances OTA-DNA adduct formation in pigs and rats, and the DNA adduct pattern is similar to that 
found in some EN patients in Croatia [52].  
Table 4. Evaluation of evidence for the “prime suspects” in the etiology of EN and UTT. 
Evidences  AA  versus  OTA 
Nephrotoxic  +    + 
Carcinogenic  +    + 
Clinical picture similarities with EN-UTT  +/-    +/- 
DNA-adducts  +?    + 
Field exposure evidences (food, urine, blood)  -    + 
Higher exposure in EN over non-EN  -    +/- 
Toxic levels  lack of evid.    + 
+ = yes; - = no; ? = under debate. Toxins 2010, 2 
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4. Conclusions 
The etiology of EN and associated UTT is still an open question. Based on epidemiological features 
of EN, researchers agree that the causative agent of both diseases is of natural origin. To resolve this 
“mystery,” certain criteria must be included in the evaluation process: (1) studies that will confirm 
exposure to the suspected agent in the EN area and evidence that the levels of exposure to this agent 
are higher than in non-EN areas; (2) toxicological studies on the biomarkers of exposure and the 
biological effects that will associate this agent with EN and UTT in humans. With respect to these 
criteria, the presented data (Table 4) pleads for the implication of OTA in the etiology of EN. Based on 
toxicity and carcinogenicity studies, OTA is a nephrotoxin and a carcinogen, but the mechanism of 
carcinogenicity remains unclear. Also, a consensus on appropriate risk metrics for OTA is lacking. 
Recently, Kuiper-Goodman et al. [65] re-evaluated risk metrics for OTA and showed that the two 
approaches converge whether one assumes a threshold mode of action (pig study [38] and modified 
uncertainty factors), or a non-threshold mode of action (rat carcinogenicity study reviewed in [21]), 
with both leading to a tolerable daily intake (TDI) or negligible cancer risk intake (NCRI) in the order 
of 4 ng kg b.w.
-1 per day. Taking into account the amounts of OTA found in food, often toxic levels 
are found, at least considering cancer development. Although OTA was detected in the food and in the 
blood of humans from non-EN parts of the world, this fact does not discard the hypothesis of the role 
of OTA in the development of EN because the population in EN region is often exposed to a higher 
amount of this toxin than in non-EN areas. Animals treated with AA or OTA displayed some features 
that are common to EN and UTT; although, there are some discrepancies, such as forestomach cancer 
in animals exposed to AA,  or sex-related renal and UTT carcinomas in those treated with OTA. 
However, extrapolation from carcinogenesis in experimental animals to humans is especially difficult. 
The  DNA-AA and DNA-OTA adducts that have been reported in EN patients and experimental 
animals are currently under debate, mainly due to DNA extraction and 
32P-postlabeling methodology. 
Nevertheless, OTA-DNA adducts have been repeatedly reported in EN patients and the structure of 
one adduct has been recently confirmed by LC-MS/MS [62]. The route of exposure to AA is doubtful 
and should be determined. Since AA undergoes extensive metabolic processing, the  exposure of 
humans to this agent should be evaluated by the measurement of AA-metabolites in fluids, as well as 
by the measurement of pure AA in food. Genotoxic action of OTA and the presence of several OTA 
metabolites in  the  blood and urine of EN patients observed by Pfohl-Leszkowicz  et al.  are solid 
arguments in favor of the hypothesis of OTA implication in EN and associated UTT development. 
More attention should be focused on molecular studies that can reveal a possible involvement of 
predisposing factors, such as the alleles for detoxifying and conjugation enzymes, since these proteins 
are involved in the  activation of many natural toxins. In addition, surveys on the  simultaneous 
occurrence of nephrotoxic mycotoxins, as well as biomarkers of exposure to such agents, should be 
further explored in both the  EN and non-EN regions, since most of the conducted biological 
investigations confirmed their synergistic, or at least additive toxic interactions.  Toxins 2010, 2 
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